Evolus, Inc.
EOLSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeEvolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. The company carries a $377.3M market cap, placing it firmly in the small-cap category. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Market Cap
$377.3M
Beta
1.32
P/E (TTM)
—
P/E (Fwd)
23.88
EPS (TTM)
$-0.67
EPS (Fwd)
$0.24
ROE
—
ROA
-9.1%
Cash
$49.8M
Total Debt
$164.9M
Free CF
-$23.2M
52W Change
-37.7%
Annual Financials
Cash vs Debt
On the balance sheet, EOLS has $49.8M in cash with $164.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$23.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $148.6M (2022) to $297.2M (2025), reflecting a 100% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Evolus, Inc.'s trajectory.